The Emergence of Trophoblast Cell-surface Antigen 2 (TROP-2) As a Novel Cancer Target

Overview

Journal Oncotarget

Specialty Oncology

Date 2018 Jul 11

PMID 29989029

Citations 120

Authors

David M Goldenberg

Rhona Stein

Robert M Sharkey

Affiliations

Soon will be listed here.

Abstract

TROP-2 is a glycoprotein first described as a surface marker of trophoblast cells, but subsequently shown to be increased in many solid cancers, with lower expression in certain normal tissues. It regulates cancer growth, invasion and spread by several signaling pathways, and has a role in stem cell biology and other diseases. This review summarizes TROP-2's properties, especially in cancer, and particularly its role as a target for antibody-drug conjugates (ADC) or immunotherapy. When the irinotecan metabolite, SN-38, is conjugated to a humanized anti-TROP-2 antibody (sacituzumab govitecan), it shows potent broad anticancer activity in human cancer xenografts and in patients with advanced triple-negative breast, non-small cell and small-cell lung, as well as urothelial cancers.

Citing Articles

Preclinical evaluation of a novel antibody-drug conjugate OBI-992 for Cancer therapy.

Chang T, Lin C, Wen S, Wu Y, Wei C, Huang J Sci Rep. 2025; 15(1):8735.

PMID: 40082588 PMC: 11906863. DOI: 10.1038/s41598-025-92697-z.

Unlocking the therapeutic potential of antibody-drug conjugates in targeting molecular biomarkers in non-small cell lung cancer.

Soni S, Megha K, Shah V, Shah A, Bhatt S, Merja M J Egypt Natl Canc Inst. 2025; 37(1):6.

PMID: 40025313 DOI: 10.1186/s43046-025-00264-4.

Targeted treatment for craniopharyngioma.

Stec N, Barker 2nd F, Brastianos P J Neurooncol. 2025; .

PMID: 39951179 DOI: 10.1007/s11060-025-04942-0.

Monitoring and management of adverse effects associated with trastuzumab deruxtecan: a UAE-specific consensus.

Dawoud E, Azribi F, Chehal A, Dawood S, Hammad S, Hamza D Front Oncol. 2025; 14:1443962.

PMID: 39882440 PMC: 11775733. DOI: 10.3389/fonc.2024.1443962.

Preclinical evaluation of zirconium-89 labeled anti-Trop2 antibody-drug conjugate (Trodelvy) for imaging in gastric cancer and triple-negative breast cancer.

Huang W, Li L, Zhou Y, Yang Q, Mixdorf J, Barnhart T Eur J Nucl Med Mol Imaging. 2025; .

PMID: 39878898 DOI: 10.1007/s00259-025-07106-4.

References

Moon S, Govindan S, Cardillo T, DSouza C, Hansen H, Goldenberg D . Antibody conjugates of 7-ethyl-10-hydroxycamptothecin (SN-38) for targeted cancer chemotherapy. J Med Chem. 2008; 51(21):6916-26. PMC: 2661425. DOI: 10.1021/jm800719t. View

Ocean A, Starodub A, Bardia A, Vahdat L, Isakoff S, Guarino M . Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics. Cancer. 2017; 123(19):3843-3854. DOI: 10.1002/cncr.30789. View

Soverini S, Mancini M, Bavaro L, Cavo M, Martinelli G . Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy. Mol Cancer. 2018; 17(1):49. PMC: 5817796. DOI: 10.1186/s12943-018-0780-6. View

Alberti S . A phosphoinositide-binding sequence is shared by PH domain target molecules--a model for the binding of PH domains to proteins. Proteins. 1998; 31(1):1-9. DOI: 10.1002/(sici)1097-0134(19980401)31:1<1::aid-prot1>3.0.co;2-r. View

Sharkey R, McBride W, Cardillo T, Govindan S, Wang Y, Rossi E . Enhanced Delivery of SN-38 to Human Tumor Xenografts with an Anti-Trop-2-SN-38 Antibody Conjugate (Sacituzumab Govitecan). Clin Cancer Res. 2015; 21(22):5131-8. DOI: 10.1158/1078-0432.CCR-15-0670. View

Stepan L, Trueblood E, Hale K, Babcook J, Borges L, Sutherland C . Expression of Trop2 cell surface glycoprotein in normal and tumor tissues: potential implications as a cancer therapeutic target. J Histochem Cytochem. 2011; 59(7):701-10. PMC: 3201164. DOI: 10.1369/0022155411410430. View

Stein R, Govindan S, Chen S, Reed L, Richel H, Griffiths G . Radioimmunotherapy of a human lung cancer xenograft with monoclonal antibody RS7: evaluation of (177)Lu and comparison of its efficacy with that of (90)Y and residualizing (131)I. J Nucl Med. 2001; 42(6):967-74. View

Sozo F, Wallace M, Zahra V, Filby C, Hooper S . Gene expression profiling during increased fetal lung expansion identifies genes likely to regulate development of the distal airways. Physiol Genomics. 2005; 24(2):105-13. DOI: 10.1152/physiolgenomics.00148.2005. View

Heist R, Guarino M, Masters G, Purcell W, Starodub A, Horn L . Therapy of Advanced Non-Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan. J Clin Oncol. 2017; 35(24):2790-2797. DOI: 10.1200/JCO.2016.72.1894. View

10.

Lin H, Zhang H, Wang J, Lu M, Zheng F, Wang C . A novel human Fab antibody for Trop2 inhibits breast cancer growth in vitro and in vivo. Int J Cancer. 2013; 134(5):1239-49. DOI: 10.1002/ijc.28451. View

11.

Alberti S . HIKE, a candidate protein binding site for PH domains, is a major regulatory region of Gbeta proteins. Proteins. 1999; 35(3):360-3. View

12.

van Rij C, Frielink C, Goldenberg D, Sharkey R, Lutje S, McBride W . Pretargeted Radioimmunotherapy of Prostate Cancer with an Anti-TROP-2×Anti-HSG Bispecific Antibody and a (177)Lu-Labeled Peptide. Cancer Biother Radiopharm. 2014; 29(8):323-9. PMC: 4186637. DOI: 10.1089/cbr.2014.1660. View

13.

Villablanca E, Renucci A, Sapede D, Lec V, Soubiran F, Sandoval P . Control of cell migration in the zebrafish lateral line: implication of the gene "tumour-associated calcium signal transducer," tacstd. Dev Dyn. 2006; 235(6):1578-88. DOI: 10.1002/dvdy.20743. View

14.

Xu P, Zhao Y, Liu K, Lin S, Liu X, Wang M . Prognostic role and clinical significance of trophoblast cell surface antigen 2 in various carcinomas. Cancer Manag Res. 2017; 9:821-837. PMC: 5731441. DOI: 10.2147/CMAR.S147033. View

15.

Dufresne A, Pivot X, Tournigand C, Facchini T, Altweegg T, Chaigneau L . Impact of chemotherapy beyond the first line in patients with metastatic breast cancer. Breast Cancer Res Treat. 2007; 107(2):275-9. DOI: 10.1007/s10549-007-9550-7. View

16.

Rossi E, Goldenberg D, Chang C . The dock-and-lock method combines recombinant engineering with site-specific covalent conjugation to generate multifunctional structures. Bioconjug Chem. 2011; 23(3):309-23. DOI: 10.1021/bc2004999. View

17.

Yang J, Zhou Y, Liu B, Wang H, Du X . Trop2 plays a cardioprotective role by promoting cardiac c-kit+ cell proliferation and inhibition of apoptosis in the acute phase of myocardial infarction. Int J Mol Med. 2013; 31(6):1298-304. DOI: 10.3892/ijmm.2013.1332. View

18.

McDougall A, Tolcos M, Hooper S, Cole T, Wallace M . Trop2: from development to disease. Dev Dyn. 2014; 244(2):99-109. DOI: 10.1002/dvdy.24242. View

19.

Trerotola M, Ganguly K, Fazli L, Fedele C, Lu H, Dutta A . Trop-2 is up-regulated in invasive prostate cancer and displaces FAK from focal contacts. Oncotarget. 2015; 6(16):14318-28. PMC: 4546469. DOI: 10.18632/oncotarget.3960. View

20.

Chang C, Wang Y, Zalath M, Liu D, Cardillo T, Goldenberg D . Combining ABCG2 Inhibitors with IMMU-132, an Anti-Trop-2 Antibody Conjugate of SN-38, Overcomes Resistance to SN-38 in Breast and Gastric Cancers. Mol Cancer Ther. 2016; 15(8):1910-9. DOI: 10.1158/1535-7163.MCT-16-0219. View